These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 30540382)
1. [Use of lipid-lowering therapy in patient with acute coronary syndrome]. Nitta S; Kasao M Nihon Rinsho; 2016 Aug; 74 Suppl 6():114-8. PubMed ID: 30540382 [No Abstract] [Full Text] [Related]
2. High intensity lipid-lowering therapy after acute coronary syndromes: room for improvement. Kostner K Med J Aust; 2019 Feb; 210(2):73-74. PubMed ID: 30712297 [No Abstract] [Full Text] [Related]
3. Acute coronary syndrome and lipid-lowering therapy in a realistic diagnostic-therapeutic care pathway. Sampietro T; Sbrana F; Dal Pino B; Bigazzi F; Palmieri C; Berti S Pharmacol Res; 2021 Sep; 171():105763. PubMed ID: 34252553 [No Abstract] [Full Text] [Related]
4. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Javed U; Deedwania PC; Bhatt DL; Cannon CP; Dai D; Hernandez AF; Peterson ED; Fonarow GC Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668 [TBL] [Abstract][Full Text] [Related]
5. A consensus statement on lipid management after acute coronary syndrome. Schiele F; Farnier M; Krempf M; Bruckert E; Ferrières J; Eur Heart J Acute Cardiovasc Care; 2018 Sep; 7(6):532-543. PubMed ID: 27856518 [TBL] [Abstract][Full Text] [Related]
6. The increasing importance of lipid lowering therapies as a part of the 'first medical contact' in patients with acute coronary syndrome. Akşit E; Küçük U; Kırılmaz B Int J Cardiol; 2024 Jul; 406():132095. PubMed ID: 38663804 [No Abstract] [Full Text] [Related]
7. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. Melloni C; Shah BR; Ou FS; Roe MT; Smith SC; Pollack CV; Ohman M; Gibler WB; Peterson ED; Alexander KP Am Heart J; 2010 Dec; 160(6):1121-9, 1129.e1. PubMed ID: 21146667 [TBL] [Abstract][Full Text] [Related]
8. Current status of lipid management in acute coronary syndrome. Fujisue K; Tsujita K J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524 [TBL] [Abstract][Full Text] [Related]
9. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Dimmitt SB; Martin JH Med J Aust; 2019 Sep; 211(6):284-284.e1. PubMed ID: 31441063 [No Abstract] [Full Text] [Related]
10. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Brieger DB; Weaver J; Kritharides L Med J Aust; 2019 Sep; 211(6):285-285.e1. PubMed ID: 31441055 [No Abstract] [Full Text] [Related]
11. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Ara R; Rafia R; Ward SE; Wierzbicki AS; Reynolds TM; Rees A; Pandor A Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):423-33. PubMed ID: 19817526 [TBL] [Abstract][Full Text] [Related]
12. [Results of complex lipid-lowering therapy in patients with a history of acute coronary syndrome]. Danio G; Márk L; Katona A Orv Hetil; 2011 Feb; 152(8):296-302. PubMed ID: 21310699 [TBL] [Abstract][Full Text] [Related]
13. Updated guidelines for percutaneous coronary intervention: what are the most important changes? Spencer BK; Smith SC Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453 [No Abstract] [Full Text] [Related]
14. Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough? Nicholls SJ; Psaltis PJ JAMA; 2018 Apr; 319(13):1325-1326. PubMed ID: 29525819 [No Abstract] [Full Text] [Related]
15. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705 [TBL] [Abstract][Full Text] [Related]
16. [Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]. Peng DD; Li ZL Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):475-7. PubMed ID: 18359719 [TBL] [Abstract][Full Text] [Related]
17. [Lipid-lowering therapy of patients suffering from acute coronary syndrome in a Hungarian county hospital in 2015]. Márk L; Nagy M; Dani G; Baranyai C; Borbély M; Katona A; Jambrik Z Orv Hetil; 2018 Mar; 159(12):478-484. PubMed ID: 29552926 [TBL] [Abstract][Full Text] [Related]
19. The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction. Gotto AM Am J Cardiol; 1998 Sep; 82(6A):1M. PubMed ID: 9766340 [No Abstract] [Full Text] [Related]
20. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]